Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D32PZT
|
|||
| Drug Name |
LY2382770
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Diabetic kidney disease [ICD-11: GB61.Z] | Phase 2 | [1] | |
| Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 2 | [2] | ||
| Company |
Eli Lilly & Co
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transforming growth factor beta (TGFB) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01113801) A Study in Participants With Diabetic Kidney Disease. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01113801) A Study in Patients With Diabetic Kidney Disease. U.S. National Institutes of Health. | |||
| REF 3 | A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.